The Wockhardt Group, once a prominent player in the pharmaceutical industry, is facing severe difficulties. With mounting debts and a struggling business, the group's significant assets are now headed to market. This sudden shift in fortunes has sent shockwaves through the industry, leaving many observers. It remains unknown who will ultimately ac